222 related articles for article (PubMed ID: 22169011)
21. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms.
Thal SC; Heinemann M; Luh C; Pieter D; Werner C; Engelhard K
J Neurotrauma; 2011 Jun; 28(6):983-93. PubMed ID: 21501066
[TBL] [Abstract][Full Text] [Related]
22. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
[TBL] [Abstract][Full Text] [Related]
23. Effects of peroxisome proliferator-activated receptor gamma agonists on Na+ transport and activity of the kinase SGK1 in epithelial cells from lung and kidney.
Wilson SM; Mansley MK; Getty J; Husband EM; Inglis SK; Hansen MK
Br J Pharmacol; 2010 Feb; 159(3):678-88. PubMed ID: 20105179
[TBL] [Abstract][Full Text] [Related]
24. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
25. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
[TBL] [Abstract][Full Text] [Related]
26. Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake.
Panchapakesan U; Pollock C; Saad S
Nephrology (Carlton); 2009 Apr; 14(3):298-301. PubMed ID: 19444964
[TBL] [Abstract][Full Text] [Related]
27. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor-gamma transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1.
Deng T; Shan S; Li PP; Shen ZF; Lu XP; Cheng J; Ning ZQ
Endocrinology; 2006 Feb; 147(2):875-84. PubMed ID: 16269451
[TBL] [Abstract][Full Text] [Related]
29. PPARγ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca(2+)]i increases in renal mesangial cells.
Koch A; Völzke A; Puff B; Blankenbach K; Meyer Zu Heringdorf D; Huwiler A; Pfeilschifter J
Biochim Biophys Acta; 2013 Nov; 1831(11):1634-43. PubMed ID: 23906789
[TBL] [Abstract][Full Text] [Related]
30. Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor.
Gras D; Chanez P; Urbach V; Vachier I; Godard P; Bonnans C
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L970-8. PubMed ID: 19346435
[TBL] [Abstract][Full Text] [Related]
31. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.
Kempná P; Hofer G; Mullis PE; Flück CE
Mol Pharmacol; 2007 Mar; 71(3):787-98. PubMed ID: 17138841
[TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.
Magenta G; Borenstein X; Rolando R; Jasnis MA
BMC Cancer; 2008 Feb; 8():47. PubMed ID: 18261208
[TBL] [Abstract][Full Text] [Related]
33. PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line.
Nofziger C; Brown KK; Smith CD; Harrington W; Murray D; Bisi J; Ashton TT; Maurio FP; Kalsi K; West TA; Baines D; Blazer-Yost BL
Am J Physiol Renal Physiol; 2009 Jul; 297(1):F55-62. PubMed ID: 19403648
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81).
Jeninga EH; Bugge A; Nielsen R; Kersten S; Hamers N; Dani C; Wabitsch M; Berger R; Stunnenberg HG; Mandrup S; Kalkhoven E
J Biol Chem; 2009 Sep; 284(39):26385-93. PubMed ID: 19633298
[TBL] [Abstract][Full Text] [Related]
36. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
37. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Benigni A; Zoja C; Tomasoni S; Campana M; Corna D; Zanchi C; Gagliardini E; Garofano E; Rottoli D; Ito T; Remuzzi G
J Am Soc Nephrol; 2006 Jun; 17(6):1624-32. PubMed ID: 16687628
[TBL] [Abstract][Full Text] [Related]
39. PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel.
Nofziger C; Chen L; Shane MA; Smith CD; Brown KK; Blazer-Yost BL
Pflugers Arch; 2005 Dec; 451(3):445-53. PubMed ID: 16170524
[TBL] [Abstract][Full Text] [Related]
40. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
